Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies

Infectious Diseases

Volumn 47, Issue 10, 2015, Pages 686-693

  Kara, Özgür ^a   Zarakolu, Pinar ^a   Aşçioʇlu, Sibel ^a   Etgül, Sezgin ^a   Uz, Burak ^a   Büyükaşik, Yahya ^a   Akova, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antimicrobial resistance; Bacteremia; Bloodstream infection; Hematologic malignancy; Neutropenia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CARBAPENEM; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CEFTAZIDIME; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; METICILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ACINETOBACTER INFECTION; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AEROMONAS; AGED; AGROBACTERIUM TUMEFACIENS; ALCALIGENES FAECALIS; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APLASTIC ANEMIA; ARTICLE; BACILLUS; BACTERIAL INFECTION; BACTERIUM ISOLATE; BREVIBACTERIUM; BRUCELLA; BRUCELLOSIS; BURKHOLDERIA GLADIOLI; BURKHOLDERIA INFECTION; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CITROBACTER; CITROBACTER FARMERI; CITROBACTER FREUNDII; CORYNEBACTERIUM; CORYNEBACTERIUM INFECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INFECTION RESISTANCE; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; KOCURIA; KOCURIA KRISTINAE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORGANELLA MORGANII; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEISSERIA ELONGATA; NEISSERIA SUBFLAVA; NEISSERIACEAE INFECTION; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OCHROBACTRUM ANTHROPI; PANTOEA AGGLOMERANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; ROTHIA MUCILAGINOSA; SALMONELLA ENTERICA SEROVAR ENTERITIDIS; SALMONELLOSIS; SERRATIA INFECTION; SERRATIA MARCESCENS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS HOMINIS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS INFECTION; TERTIARY HEALTH CARE; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL; VANCOMYCIN RESISTANT ENTEROCOCCUS; ADOLESCENT; BACTEREMIA; CLASSIFICATION; COMPLICATION; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; ISOLATION AND PURIFICATION; KLEBSIELLA; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; STAPHYLOCOCCUS AUREUS; TERTIARY CARE CENTER; TIME FACTOR; TURKEY; VERY ELDERLY; YOUNG ADULT;

ACINETOBACTER; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HEMATOLOGIC NEOPLASMS; HUMANS; KLEBSIELLA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TERTIARY CARE CENTERS; TIME FACTORS; TURKEY; YOUNG ADULT;

EID: 84962514723     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/23744235.2015.1051105     Document Type: Article

References (41)

1. Sacar S, Hacioglu SK, Keskin A, Turgut H.Evaluation of febrile neutropenic attacks in a tertiary care medical center in Turkey JInfect Dev Ctries 2008; 2: 359-63.
2. Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, et al Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia Epidemiol Infect 2010; 138: 1044-51.
3. Cattaneo C, Quaresmini G, Casari S ,C apucci MA, Micheletti M, Borlenghi E, et al Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with hematological malignancies: results of a prospective study on 823 patients at a single institution J Antimicrob Chemother 2008; 61: 721-8.
4. Arnan M, Gudiol C, Calatayud L, Liñ a res J, Dominguez M Á, Batlle M, et al Risk factors for, and clinical relevance of, faecal extended-spectrum ?-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies Eur J Clin Microbiol Infect Dis 2011; 30: 355-60.
5. Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sánchez-Ortega I, et al Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes JAntimicrob Chemother 2011; 66: 657-63.
6. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB Current trends in the epidemiology of nosocomial bloodstream infections in patients with haematological malignancies and solid neoplasms in hospitals in the United States Clin Infect Dis 2003; 36: 1103-10.
7. Ramphal R.Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens Clin Infect Dis 2004; 39: S25-S31.
8. Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, et al ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011) Haematologica 2013; 98: 1836-47.
9. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia Haematologica 2013; 98: 1826-35.
10. Zinner SH Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria Clin Infect Dis 1999; 29: 490-4.
11. Elting LS, Bodey GP, Keefe BH Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors Clin Infect Dis 1992; 14: 1201-7.
12. Cordonnier C, Buzyn A, Leverger G, Herbrecht R, Hunault M, Leclercq R, et al Club de Réflexion sur les Infections en Onco-Hématologie Epidemiology and risk factors for Grampositive coccal infections in neutropenia: toward a more targeted antibiotic strategy Clin Infect Dis 2003; 36: 149-58.
13. M ikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al Fourth European Conference on Infections in Leukemia Group (ECIL-4), a joint venture of EBMT, EORTC, ICHS, ELN and ESGICH/ESCMID Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients JInfect 2014; 68: 321-31.
14. Wojak I, Gospodarek E.Analysis of microorganisms isolated from febrile neutropenic children with neoplastic disease Med Dosw Mikrobiol 2004; 56: 411-19.
15. Tumbarello M, Spanu T, Caira M, Trecarichi EM, Laurenti L, Montuori E, et al Factors associated with mortality in bacteremic patients with hematologic malignancies Diagn Microbiol Infect Dis 2009; 64: 320-6.
16. Nicoletti G, Schito G, Fadda G, Boros S, Nicolosi D, Marchese A, et al CIGAR (Gruppo Cooperativo Infezioni Gravi ed Antibiotico Resistenza) Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting JChemother 2006; 18: 589-602.
17. Rolston K.The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients Int J Infect Dis 2006; 10: 223-30.
18. Gafter-Gvili A, Fraser A, Paul M, van de Wetering M, Kremer L, Leibovici L.Antibiotic prophylaxis for bacterial infections in a febrile neutropenic patients following chemotherapy Cochrane Database Syst Rev 2005; 19: CD004386.
19. Safdar A, Rolston K.Stenotrophomonas maltophilia: changing spectrum of serious bacterial pathogens in patients with cancer Clin Infect Dis 2007; 45: 1602-9.
20. Hughes W T, Armstrong D, Bodey G P, Bow E J, Brown AE, Calandra T, et al 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer Clin Infect Dis 2002; 34: 730-51.
21. Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, et al Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients Clin Microbiol Infect 2013; 19: 474-9.
22. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement M100-S18 CLSI; 2008.
23. Magiorakos A P, Srinivasan A, Carey R B, Carmeli Y, Falagas M E, Giske CG, et al Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 2012; 18: 268-81.
24. A rmitage P.Test for linear trend in proportions and frequencies Biometrics 1955; 11: 375-86.
25. Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al Incidence and clinical impact of extendedspectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies J Infect 2009; 58: 299-307.
26. Gençer S, Bat? rel A, Özer S.The antibiotic susceptibilities of bacteria isolated from febrile neutropenic patients Flora 2003; 8: 207-12.
27. Akova M, Akan H.Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics Int J Antimicrob Agents 1999; 13: 15-19.
28. Sigurdardottir K, Digranes A, Harthug S, Nesthus I, Tangen JM, Dybdahl B, et al Amulti-centre prospective study of febrile neutropenia in Norway: microbiological findings and antimicrobial susceptibility Scand J Infect Dis 2005; 37: 455-64.
29. Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Mu ñ oz A, et al Analysis of 4758 Escherichia coli bacteremia episodes: predictive factors for isolation of an antibioticresistant strain and their impact on outcome JAntimicrob Chemother 2009; 63: 568-74.
30. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al.; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program Levofl oxacin to prevent bacterial infection in patients with cancer and neutropenia NEngl J Med 2005; 353: 977-87.
31. Pitout J D, Laupland K B.Extended-spectrum betalactamaseproducing enterobacteriaceae: an emerging public health concern Lancet Infect Dis 2008; 8: 159-66.
32. Rodríguez-Bañ o J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al Community infections caused by extendedspectrum ?-lactamase producing Escherichia coli Arch Intern Med 2008; 168: 1897-902.
33. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F.Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin Clin Infect Dis 1995; 20: 557-60.
34. Yagci D, Yoruk F, Azap A, Memikoglu O.Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy Antimicrob Agents Chemother 2009; 53: 1287-9.
35. Winokur P L, Canton R, Casellas J M, Legakis N.Variations in the prevalence of strains expressing beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region Clin Infect Dis 2001; 15: 94-103.
36. Zarakolu, P, Hasç elik G, Ü nal S.Antimicrobial susceptibility pattern of nosocomial Gram negative pathogens: MYSTIC study results in Hacettepe University Adult Hospital (2000-2004) Mikrobiyol Bult 2006; 40: 147-54.
37. McDonald P, Mitchell E, Johnson H, Rossney A, Humphreys H, Glynn G, et al Epidemiology of MRSA: the North/South study of MRSA in Ireland 1999 JHosp Infect 2003; 54: 130-4.
38. MacKenzie FM, Bruce J, Struelens MJ, Goossens H, Mollison J, Gould IM ARPAC Steering Group Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals Clin Microbiol Infect 2007; 13: 269-76.
39. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A.BSAC extended working party on bacteraemia resistance surveillance Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme JAntimicrob Chemother 2004; 53: 1018-32.
40. Elmaataoui A, Elghazouani M, Eric NA, Doghmi K, Mikdame M, Elhamzaoui S, et al Blood isolates epidemiology in a clinical haematology department Ann Biol Clin (Paris) 2009; 67: 293-7.
41. Cattaneo C, Casari S, Bracchi F, Signorini L, Ravizzola G, Borlenghi E, et al Recent increase in enterococci, viridans streptococci, Pseudomonas spp and multiresistant strains among haematological patients, with a negative impact on outcome Results of a 3-year surveillance study at a single institution Scand J Infect Dis 2010; 42: 324-32